Cancer Family
Malignant Peritoneal and Retroperitoneal Neoplasm
CI-CAN-00000248Explore in graph →
163 active trials6 approved drugs2 evidence items
- NCIt
- C156711
Loading cancer entity…
Cancer Family
CI-CAN-00000248Explore in graph →
Clinical trials
631 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (92)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00331422 | Carboplatin, Paclitaxel, and Surgery in Treating Patients With Advanced Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer | terminated | Phase 2 | 7 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Dec 28, 2017 | clinicaltrials |
| NCT00652899 | Allogeneic Natural Killer Cells in Patients With Recurrent Ovarian Cancer, Fallopian Tube, and Primary Peritoneal Cancer | terminated | Phase 2 | 14 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Dec 28, 2017 |
| clinicaltrials |
| NCT00903630 | Lenalidomide and Doxorubicin Hydrochloride Liposome in Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer | terminated | Phase 1 / Phase 2 | 15 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Dec 28, 2017 | clinicaltrials |
| NCT01145430 | Veliparib and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer or Metastatic Breast Cancer | completed | Phase 1 | 45 | National Cancer Institute (NCI)NIH | 1 | Dec 22, 2017 | clinicaltrials |
| NCT02328716 | Cytoreduction With or Without Intraoperative Intraperitoneal Hyperthermic Chemotherapy (HIPEC) in Patients With Peritoneal Carcinomatosis From Ovarian Cancer, Fallopian Tube or Primary Peritoneal Carcinoma(CARCINOHIPEC) | unknown | Phase 3 | 32 | Fundacion para la Formacion e Investigacion Sanitarias de la Region de MurciaOTHER | 1 | Dec 13, 2017 | clinicaltrials |
| NCT02118285 | Intraperitoneal Natural Killer Cells and INCB024360 for Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer | completed | Phase 1 | 2 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Dec 5, 2017 | clinicaltrials |
| NCT00287859 | Topotecan in Treating Patients With Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer | terminated | Phase 1 | 5 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Nov 29, 2017 | clinicaltrials |
| NCT00287885 | Docetaxel in Treating Patients With Refractory or Recurrent Advanced Gynecologic Cancer | completed | Phase 1 | 18 | Masonic Cancer Center, University of MinnesotaOTHER | 0 | Nov 29, 2017 | clinicaltrials |
| NCT00625092 | Hyperthermic Intraperitoneal Oxaliplatin for Peritoneal Malignancies | completed | Phase 1 | 17 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Nov 29, 2017 | clinicaltrials |
| NCT01264432 | Veliparib and Radiation Therapy in Treating Patients With Advanced Solid Malignancies With Peritoneal Carcinomatosis, Epithelial Ovarian, Fallopian, or Primary Peritoneal Cancer | completed | Phase 1 | 34 | National Cancer Institute (NCI)NIH | 2 | Nov 21, 2017 | clinicaltrials |
| NCT01898715 | Phase 1 Study of ATR-101 in Subjects With Advanced Adrenocortical Carcinoma | completed | Phase 1 | 63 | Millendo Therapeutics, Inc.INDUSTRY | 2 | Nov 6, 2017 | clinicaltrials |
| NCT02831179 | Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor | withdrawn | Phase 1 | 0 | Vanderbilt-Ingram Cancer CenterOTHER | 0 | Sep 28, 2017 | clinicaltrials |
| NCT01039207 | Rilotumumab in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer | completed | Phase 2 | 31 | Gynecologic Oncology GroupNETWORK | 1 | Sep 7, 2017 | clinicaltrials |
| NCT00354601 | Docetaxel and Capecitabine in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cavity Cancer | terminated | Phase 2 | 2 | Wake Forest University Health SciencesOTHER | 1 | Aug 30, 2017 | clinicaltrials |
| NCT00004221 | Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Stage III Ovarian Cancer | terminated | Phase 2 | 12 | Gynecologic Oncology GroupNETWORK | 1 | Aug 9, 2017 | clinicaltrials |
| NCT01905163 | Feasibility of Interval Debulking Surgery by Laparoscopy for Peritoneal Carcinosis in Chemosensitive Patients(CILOVE) | completed | Phase 2 | 47 | Centre Jean PerrinOTHER | 1 | Jul 19, 2017 | clinicaltrials |
| NCT00045682 | CT-2103 in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer or Primary Peritoneal Cancer | completed | Phase 2 | 78 | Gynecologic Oncology GroupNETWORK | 1 | Jul 13, 2017 | clinicaltrials |
| NCT00054119 | Karenitecin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer or Primary Peritoneal Cancer | completed | Phase 2 | 27 | Gynecologic Oncology GroupNETWORK | 1 | Jul 13, 2017 | clinicaltrials |
| NCT00511992 | Study of Bevacizumab Followed by Bevacizumab Consolidation for Ovarian Cancer | completed | Phase 2 | 20 | University of OklahomaOTHER | 1 | Jul 2, 2017 | clinicaltrials |
| NCT00061308 | Second-line Intravenous Treatment For Recurrent Platinum-Sensitive Ovarian, Fallopian, Or Peritoneal Cancer | completed | Phase 2 | 75 | GlaxoSmithKlineINDUSTRY | 2 | Jun 9, 2017 | clinicaltrials |
| NCT01972516 | Tivozanib As Maintenance Therapy In GYN | terminated | Phase 2 | 4 | Dana-Farber Cancer InstituteOTHER | 1 | Jun 5, 2017 | clinicaltrials |
| NCT01175343 | RO4929097 in Treating Patients With Recurrent and/or Metastatic Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer | completed | Phase 2 | 45 | National Cancer Institute (NCI)NIH | 2 | May 24, 2017 | clinicaltrials |
| NCT03145285 | Activity of Abiraterone Acetate in the Management of Cushing's Syndrome in Patients With Adrenocortical Carcinoma(ABACUS) | unknown | Phase 2 | 10 | Azienda Socio Sanitaria Territoriale degli Spedali Civili di BresciaOTHER | 1 | May 10, 2017 | clinicaltrials |
| NCT00777244 | Efficacy of Adjuvant Mitotane Treatment (ADIUVO)(ADIUVO) | unknown | Phase 3 | 200 | University of Turin, ItalyOTHER | 7 | May 8, 2017 | clinicaltrials |
| NCT02741167 | Pathophysiology of Inflammation After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy | unknown | — | 90 | University of ZurichOTHER | 1 | May 4, 2017 | clinicaltrials |
| NCT01514526 | Clinical Trial of Dovitinib in First-line Metastatic or Locally Advanced Non-resectable Adrenocortical Carcinoma | completed | Phase 2 | 17 | Spanish Oncology Genito-Urinary GroupOTHER | 1 | Apr 25, 2017 | clinicaltrials |
| NCT01138137 | N-acetylcysteine Given IV With Cisplatin and Paclitaxel in Patients With Ovarian Cancer | withdrawn | Phase 1 | 0 | OHSU Knight Cancer InstituteOTHER | 1 | Apr 21, 2017 | clinicaltrials |
| NCT01416038 | Phase 1 Study of a Cancer Vaccine to Treat Patients With Advanced Stage Ovarian, Fallopian or Peritoneal Cancer | completed | Phase 1 | 19 | ImmunoVaccine Technologies, Inc. (IMV Inc.)INDUSTRY | 2 | Apr 21, 2017 | clinicaltrials |
| NCT01248273 | Unimolecular Pentavalent (Globo-H-GM2-sTn-TF-Tn) Immunization of Patients With Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer in First Remission | completed | Phase 1 | 26 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Mar 14, 2017 | clinicaltrials |
| NCT01137071 | Consolidation Therapy With Hu3S193 for Women With Ovarian, Primary Peritoneal or Fallopian Tube Cancer | terminated | Phase 2 | 29 | Recepta BiopharmaINDUSTRY | 1 | Feb 23, 2017 | clinicaltrials |
| NCT01493505 | TRINOVA-3: A Study of AMG 386 or AMG 386 Placebo in Combination With Paclitaxel and Carboplatin to Treat Ovarian Cancer | terminated | Phase 3 | 1,015 | AmgenINDUSTRY | 14 | Feb 23, 2017 | clinicaltrials |
| NCT00901836 | Preoperative Proton Radiotherapy for Retroperitoneal Sarcoma(SA03) | terminated | N/A | 2 | University of FloridaOTHER | 1 | Feb 10, 2017 | clinicaltrials |
| NCT00445718 | Natural History Study of Infants With Adrenal Masses Found on Prenatal and/or Neonatal Imaging | completed | — | 97 | Children's Oncology GroupNETWORK | 3 | Feb 9, 2017 | clinicaltrials |
| NCT01308944 | Therapeutic Targeting of Stress Factors in Ovarian Cancer Patients | completed | Phase 1 | 24 | Washington University School of MedicineOTHER | 1 | Jan 12, 2017 | clinicaltrials |
| NCT01669226 | First-line Intraperitoneal Cisplatin and Etoposide Chemotherapy for Ovarian Cancer(AICE) | completed | Phase 2 | 215 | Shanghai Gynecologic Oncology GroupOTHER_GOV | 1 | Dec 19, 2016 | clinicaltrials |
| NCT00637390 | A Phase I Study of Alemtuzumab in Patients With Relapsed Ovarian/Primary Peritoneal Cancer. | terminated | Phase 1 | 3 | University of Michigan Rogel Cancer CenterOTHER | 1 | Dec 2, 2016 | clinicaltrials |
| NCT00897442 | Collecting Tumor Samples From Patients With Gynecological Tumors | completed | — | 275 | Gynecologic Oncology GroupNETWORK | 1 | Oct 28, 2016 | clinicaltrials |
| NCT01704651 | Accelerating Gastrointestinal Recovery | completed | Phase 3 | 146 | Jamie N. Bakkum-GamezOTHER | 1 | Oct 24, 2016 | clinicaltrials |
| NCT00094497 | Trial in Locally Advanced and Metastatic Adrenocortical Carcinoma Treatment (FIRM-ACT) | completed | Phase 3 | 304 | Collaborative Group for Adrenocortical Carcinoma TreatmentOTHER | 8 | Sep 21, 2016 | clinicaltrials |
| NCT01031381 | Study of RAD001 and Bevacizumab in Recurrent Ovarian, Peritoneal, and Fallopian Tube Cancer(RADBEV) | completed | Phase 2 | 50 | University of PittsburghOTHER | 1 | Aug 30, 2016 | clinicaltrials |
| NCT00602277 | Viral Therapy in Treating Patients With Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer That Did Not Respond to Platinum Chemotherapy | completed | Phase 1 | 70 | National Cancer Institute (NCI)NIH | 1 | Aug 8, 2016 | clinicaltrials |
| NCT02595021 | Total/Subtotal Colectomy in Ovarian Cancer | unknown | Phase 2 | 80 | Shanghai Gynecologic Oncology GroupOTHER_GOV | 1 | Jul 26, 2016 | clinicaltrials |
| NCT02627430 | Talazoparib and HSP90 Inhibitor AT13387 in Treating Patients With Metastatic Advanced Solid Tumor or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple Negative Breast Cancer | withdrawn | Phase 1 | 0 | National Cancer Institute (NCI)NIH | 0 | Jul 26, 2016 | clinicaltrials |
| NCT01283035 | A Phase II Study of Akt Inhibitor MK2206 in the Treatment of Recurrent Platinum-Resistant Ovarian, Fallopian Tube, or Peritoneal Cancer | completed | Phase 2 | 6 | National Cancer Institute (NCI)NIH | 1 | Jun 24, 2016 | clinicaltrials |
| NCT01528956 | Studying Genes in Samples From Younger Patients With Adrenocortical Tumor | completed | — | 10 | Children's Oncology GroupNETWORK | 0 | May 18, 2016 | clinicaltrials |
| NCT01447706 | A Study of MM-121 With Paclitaxel in Platinum Resistant/ Refractory Advanced Ovarian Cancers | completed | Phase 2 | 223 | Merrimack PharmaceuticalsINDUSTRY | 1 | May 12, 2016 | clinicaltrials |
| NCT00634894 | Femara (Letrozole) Versus Placebo for Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | withdrawn | Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 20, 2016 | clinicaltrials |
| NCT00671788 | A Phase II Evaluation of Dasatinib (Sprycel®, NSC #732517) in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma | completed | Phase 2 | 35 | Gynecologic Oncology GroupNETWORK | 1 | Apr 15, 2016 | clinicaltrials |
Data updated 23 days agoSource updated Dec 28, 2017source: clinicaltrials